Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by ...
Pharmaceutical Technology on MSN
CSL to pump $1.5bn into US plasma supply chain
CSL said the investment reflects the growing need for immunoglobulin, though it did not reveal detailed manufacturing plans.
Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback